Core Insights - Profusa, Inc. has established a new distributor partnership with MedSell in France to commercialize Lumee™ Oxygen tissue monitoring, expanding its reach in the European market [1][2] - The partnership aims to address the needs of approximately 200,000 annual Critical Limb Threatening Ischemia (CLTI) cases in the European Union, with MedSell focusing on hospital and outpatient care settings [1][2] - The collaboration with MedSell complements an existing partnership with a leading vascular surgeon in France, who accounts for about 8% of all CLTI cases in the country [2] Company Strategy - Profusa aims to achieve $200 to $250 million in revenue by 2030, with projected revenues of $0.5 to $2 million in 2026 and $9 to $13 million in 2027 [3] - The company is focused on executing its commercial strategies, including the introduction of Lumee Oxygen monitoring in Europe starting in Q2 2026, with plans to enter the US market in 2027 [3] - Profusa emphasizes the importance of making its oxygen tissue monitoring platform accessible in both clinical and home settings to enhance patient outcomes and reduce healthcare costs [3] Product Overview - Lumee Oxygen tissue monitoring is designed to measure tissue oxygen perfusion before and during surgical procedures, as well as during follow-up care, addressing a critical unmet clinical need [2] - The device is expected to provide significant value to clinicians by supporting decision-making and patient monitoring throughout the treatment pathway [2] - Profusa's technology is part of a broader initiative to develop tissue-integrated sensors that continuously transmit actionable medical data [4]

Core Insights - Shenzhen has produced a number of globally impactful companies, showcasing a shift from "Made in China" to "Created in China" [2] - The 45th anniversary of Shenzhen Special Economic Zone marks a significant milestone in its rapid modernization and brand development [2][3] - The "Shenzhen Brand Development White Paper (1980-2025)" outlines the evolution of Shenzhen's brands and their internal logic and success factors [3][5] Group 1: Brand Evolution - Shenzhen's brand journey reflects a transition from manufacturing to innovation, with key phases including the emergence of local brands in the 1980s and 1990s, and the rise of autonomous brands in the early 2000s [7][10] - The current phase is characterized by cluster upgrades, with companies like Tencent, BYD, and DJI leading in various sectors [8][10] - As of now, Shenzhen has cultivated 1,220 notable local brands, including 13 billion-level brands and 7 trillion-level brands, with Tencent, Ping An, and Huawei each exceeding a brand value of 490 billion [10][11] Group 2: Economic Contributions - The 1,220 notable brands contribute 47.97% of the city's sales, 42.05% of tax revenue, and 32.87% of exports, serving as the backbone of Shenzhen's high-quality economic development [11] - These brands span critical sectors such as electronics, renewable energy, biomedicine, high-end equipment, financial services, and digital economy, forming a robust industrial structure [11] Group 3: Brand Development Factors - Shenzhen's brand success is attributed to a unique ecosystem supported by policy innovation, technological advancement, and collaborative industrial frameworks [15][16][19] - The government has played a crucial role in creating a conducive environment for brand growth through targeted policies and regulatory frameworks [16] - Innovation drives brand competitiveness, with companies investing over 10% of their annual revenue in R&D, fostering a comprehensive innovation ecosystem [17] Group 4: Global Expansion and Responsibility - Shenzhen brands have established clear pathways for international expansion, evolving from processing trade to localized operations and global standardization [20] - Social responsibility is ingrained in the corporate strategy, enhancing brand value and sustainability through practices like tax compliance and community support [21] Group 5: Future Outlook - The release of the white paper is a significant step in documenting Shenzhen's brand journey and providing strategic guidance for future brand development [31] - Shenzhen's brands are expected to continue thriving in emerging sectors like digital and low-altitude economies, contributing to the global narrative of Chinese brands [33][34]

Core Viewpoint - The lawsuit against Inspire Medical Systems, Inc. alleges that the company made misleading statements regarding the demand and launch of its implantable medical device for obstructive sleep apnea, leading to significant financial losses for investors [1][2]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who acquired Inspire securities between August 6, 2024, and August 4, 2025 [1]. - Allegations include that the company failed to disclose poor demand for its product and had surplus inventory, which affected the transition to the new treatment [1]. - The lawsuit claims that Inspire Medical did not complete essential tasks for a successful product launch, contrary to their public assurances [1]. Group 2: Financial Impact - On August 4, 2025, Inspire Medical announced that the launch of Inspire V was delayed due to incomplete training and onboarding at treatment centers [2]. - The company admitted that software updates necessary for billing were not effective until July 1, leading many centers to continue using an earlier version of the product [2]. - Following the announcement, Inspire's stock price dropped by $42.04, or approximately 32.35%, from $129.95 to $87.91 per share [2].

Corporate Update - MedMira Inc. reported its financial results for the quarter ended October 31, 2025 [1] - The company received Health Canada approval for its Reveal® TP (Syphilis) rapid test in Q1 FY2026 [1]

Core Viewpoint - The global IPO market is expected to fully recover by 2025, primarily supported by a fundamental shift in the global liquidity environment as major central banks, led by the Federal Reserve, begin to lower interest rates after a period of aggressive rate hikes since 2022 [2] Group 1: Market Dynamics - The Hong Kong stock market has regained its position as the top global IPO fundraising market, with total IPO fundraising expected to reach HKD 2787.03 billion (approximately USD 359 billion), surpassing the Nasdaq's USD 258 billion, marking the highest level since 2021 [6] - The influx of capital from both domestic and international investors has created a dual-driven dynamic in the Hong Kong market, providing significant liquidity support for large IPO projects [2][4] - The number of IPO applications processed by the Hong Kong Stock Exchange has surged to 331, up from 84 at the beginning of the year, indicating a potential acceleration in IPO transactions towards the end of the year [4][19] Group 2: Notable IPOs - The largest IPO in Hong Kong this year was by Contemporary Amperex Technology Co., Ltd. (宁德时代), raising HKD 310.06 billion (approximately USD 39.88 billion) with a cumulative increase of 89.28% since listing [12] - Other significant IPOs include Zijin Mining's spin-off, which raised HKD 249.84 billion (approximately USD 32.14 billion), and the listing of Seres, which raised HKD 131.76 billion (approximately USD 16.95 billion) [12] Group 3: Future Outlook - The IPO market is expected to become more crowded in 2026, with a significant number of companies, particularly in the technology and innovation sectors, preparing for potential listings [16][18] - Major companies like SpaceX and AI leaders such as OpenAI and Anthropic are anticipated to initiate IPO processes, which could lead to the largest IPO wave in history [18] - The Hong Kong market may face challenges due to a backlog of IPO applications, which could exacerbate competition in the global IPO landscape [19][20]

Core Viewpoint - Profound Medical Corp. has successfully completed a private placement of common shares, raising approximately US$6.45 million to support its business expansion and development efforts [1][2]. Group 1: Offering Details - The company issued a total of 921,428 common shares at a price of US$7.00 per share [1]. - The shares are subject to a hold period of four months plus one day from the closing date under Canadian securities laws [2]. - The net proceeds from the offering will be allocated for sales and marketing expansion, working capital, research and development, strategic transactions, and general corporate purposes [2]. Group 2: Regulatory Information - The securities offered have not been registered under the U.S. Securities Act and cannot be sold in the U.S. without registration or an applicable exemption [3]. - The company plans to file a registration statement with the U.S. Securities and Exchange Commission within four months from the closing date of the offering [3]. Group 3: Company Overview - Profound Medical Corp. is a commercial-stage medical device company focused on AI-powered, MRI-guided, incision-free therapies for tissue ablation [5]. - The company is commercializing TULSA-PRO, a technology designed for the treatment of various prostate conditions, which is CE marked, Health Canada approved, and FDA 510(k) cleared [6]. - Profound is also developing Sonalleve, a therapeutic platform for treating uterine fibroids and other conditions, which has received CE marking and FDA approval under a Humanitarian Device Exemption [7].

Core Viewpoint - CeriBell, Inc. is set to present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its focus on transforming the diagnosis and management of serious neurological conditions [1][2]. Group 1: Company Overview - CeriBell, Inc. is a medical technology company dedicated to improving the diagnosis and management of patients with serious neurological conditions [3]. - The company has developed the Ceribell System, a novel point-of-care electroencephalography (EEG) platform designed for acute care settings [3]. - The Ceribell System combines portable hardware with AI-powered algorithms for rapid diagnosis and continuous monitoring of neurological conditions [3]. - The system is FDA-cleared for detecting seizures and delirium in intensive care units and emergency rooms across the U.S. [3]. Group 2: Upcoming Event - Jane Chao, Ph.D., CEO and Co-founder of CeriBell, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 9:00 am PST / 12:00 pm EST [1][2]. - A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website [2].

Core Viewpoint - Treace Medical Concepts, Inc. is set to present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its innovative approach in the surgical treatment of bunions and related midfoot deformities [1] Group 1: Company Overview - Treace Medical Concepts is a medical technology company focused on improving surgical management standards for bunions and midfoot deformities, which affect approximately 67 million Americans [4] - The company estimates that 1.1 million Americans are annual surgical candidates for bunion treatment [4] - Treace has developed the patented Lapiplasty 3D Bunion Correction System, which addresses the root cause of bunions by correcting deformities in all three planes and stabilizing the affected joint [4] Group 2: Product Offerings - In addition to the Lapiplasty system, Treace offers the Adductoplasty Midfoot Correction System for midfoot deformities and two minimally invasive osteotomy systems: the Nanoplasty 3D and the Percuplasty™ systems [4] - The company also provides the SpeedMTP MTP Fusion System and is expanding its SpeedPlate rapid compression implant platform for new applications [4] - Treace enhances surgical planning with its IntelliGuide™ technology, which offers patient-specific pre-operative planning and cut guide solutions [4] Group 3: Investor Relations - Treace encourages investors to regularly check its website for important updates and information [3] - A live webcast of the upcoming presentation will be available on the company's investor relations website [2]

TABLE OF CONTENTS REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 30, 2025 Registration No. 333-290244 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENCORE MEDICAL, INC. (Exact name of registrant as specified in its charter) 3841 (Primary Standard Industrial Classification Code Number) Minnesota (State or other jurisdiction of inc ...

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [5][4]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, a decrease from the previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations. The company also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6]. Legal Proceedings - Investors have until February 9, 2026, to request to lead the case in the U.S. District Court for the Southern District of New York, under the case caption West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al. [3]. Legal Representation - Bleichmar Fonti & Auld LLP, a leading international law firm, is representing the plaintiffs in this class action lawsuit, having a strong track record in securities class actions and shareholder litigation [8].